Royce & Associates LP Grows Stock Position in Ingevity Co. (NYSE:NGVT)

Royce & Associates LP boosted its position in Ingevity Co. (NYSE:NGVT - Free Report) by 22.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,142,598 shares of the company's stock after buying an additional 208,921 shares during the period. Royce & Associates LP owned approximately 3.14% of Ingevity worth $46,561,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of NGVT. First Horizon Advisors Inc. lifted its holdings in shares of Ingevity by 45.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 862 shares of the company's stock valued at $34,000 after buying an additional 271 shares during the period. KBC Group NV lifted its holdings in Ingevity by 50.8% in the third quarter. KBC Group NV now owns 1,574 shares of the company's stock valued at $61,000 after acquiring an additional 530 shares during the period. Empowered Funds LLC acquired a new stake in Ingevity in the fourth quarter valued at $187,000. Aigen Investment Management LP purchased a new stake in shares of Ingevity during the 3rd quarter worth $231,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of Ingevity during the 4th quarter worth $239,000. 91.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. StockNews.com raised shares of Ingevity from a "hold" rating to a "buy" rating in a report on Thursday, February 20th. BMO Capital Markets raised Ingevity from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $62.00 to $65.00 in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Ingevity has a consensus rating of "Moderate Buy" and an average target price of $55.17.

Remove Ads

Ingevity Price Performance

Shares of NYSE:NGVT traded down $1.16 on Thursday, hitting $43.09. The company had a trading volume of 178,187 shares, compared to its average volume of 255,731. The company has a market cap of $1.57 billion, a PE ratio of -3.64 and a beta of 1.53. The business has a 50 day moving average of $45.09 and a 200 day moving average of $42.25. Ingevity Co. has a 52-week low of $30.90 and a 52-week high of $56.30. The company has a current ratio of 1.87, a quick ratio of 1.04 and a debt-to-equity ratio of 6.86.

Ingevity (NYSE:NGVT - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.66. The company had revenue of $298.80 million for the quarter, compared to analyst estimates of $297.40 million. Ingevity had a negative net margin of 30.60% and a positive return on equity of 41.44%. As a group, equities analysts anticipate that Ingevity Co. will post 4.45 earnings per share for the current fiscal year.

Ingevity Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.